Atul Khajuria,
Ashish Kumar,
- Professor, University School of Allied and Health Care Sciences Rayat Bahra Professional University VPO BOHAN, Tehsil & Distt. Hoshiarpur, Punjab, India
- Assistant Professor, University School of Medical Laboratory Sciences Rayat Bahra Professional University VPO BOHAN, Tehsil &Dist. Hoshiarpur, Punjab, India
Abstract
DNA replication timing serves as a fundamental epigenetic feature that organizes genome function during the cell cycle (3), while anti-cancer drugs profoundly alter this process to disrupt tumor growth(4). These agents target chromatin architecture, shifting replication domains and reshaping mutational patterns critical for cancer evolution (1,5). DNA replication timing (RT) domains serve as dynamic epigenetic organizers, partitioning the genome into early- and late-replicating regions that correlate with chromatin states, gene activity, and mutational vulnerability in cancer. Anti-cancer drugs, including chemotherapeutic agents like platinum compounds, alkylators, and epigenetic modulators (e.g., HDAC inhibitors, DNA methyltransferase inhibitors), profoundly reprogram RT programs, inducing shifts from stable early- replicating euchromatin to delayed late-replicating heterochromatin enriched in H3K27me3 and hypomethylated CpG islands. This pharmacoepigenomic rewiring disrupts topologically associating domains (TADs), promotes long-range chromatin interactions, and elevates replication stress, fostering double-strand breaks preferentially in late-replicating loci prone to facultative heterochromatin transitions. Emerging evidence reveals that such RT alterations underpin therapy-induced mutational landscapes, with early-replicating regions susceptible to translocations due to heightened transcription-replication conflicts, while late-replicating zones accumulate kataegis-like signatures from APOBEC hyperactivity and error- prone repair. In preclinical models and survivor cohorts, adolescent chemotherapy exposure imprints persistent sperm epimutations—differentially methylated regions (DMRs) in CpG deserts—suggesting intergenerational inheritance of altered RT domains that may predispose offspring to genomic instability. Clinical pharmacoepigenomic profiling, integrating Repli-seq, ATAC-seq, and whole-genome bisulfite sequencing, demonstrates that RT shifts predict therapy response and relapse, as seen in breast and prostate cancers where late-RT domains correlate with aggressive epigenomic deregulation.
Keywords: pharmacoepigenomics, replication timing, chromatin domains, anticancer drugs, mutational landscapes
[This article belongs to International Journal of Molecular Biotechnological Research ]
References
1. Rivera-Mulia JC, Buckley Q, Sasaki T, Zimmerman J, Didier RA, Nazor KL, et al. Replication timing and epigenome remodelling are associated with the nature of pluripotency. Nat Commun. 2019;10(1):4239. doi:10.1038/s41467-019-08302-1.
2. Gilbert DM. DNA replication timing, genome stability and cancer. Front Genet. 2013;4:19. doi:10.3389/fgene.2013.00019.
3. Bontemps-Gallo S, Andric V, Hubé F, Guérin M, Gilson E, Lemaitre JM, et al. Chromatin as an old and new anti-cancer target. Cancer Res Commun. 2024;[vol(issue)]:[pages]. PMID:11479676.
4. Sharifi N, et al. The pharmacoepigenomic landscape of cancer cell lines. Academia.edu; 2023. Available from: https://www.academia.edu.
5. Hiratani I, Ryba T, Itoh M, Yokochi T, Schwaiger M, Chang CW, et al. Global reorganization of replication domains during embryonic stem cell differentiation. PLoS Biol. 2009;6(10):e245. doi:10.1371/journal.pbio.0060245.
6. Fox Chase Cancer Center. Study provides new insights into DNA replication timing and genomic instability. Fox Chase News Release. 2021. Available from: https://www.foxchase.org.
7. Zhang X, Sima N, Li D, et al. Leveraging chromatin packing domains to target chemoevasion in cancer. bioRxiv [Preprint]. 2025. doi:10.1101/2025.01.21.12318189.
8. Desprat R, Thierry-Mieg D, Lailler N, Lajugie J, Schildkraut CL, Gilbert DM, Arneodo A, et al. Predictable dynamic programme of timing of DNA replication in human cells. Genome Biol. 2009;10(8):R80. doi:10.1186/gb-2009-10-8-r80.
9. Ryba T, Hiratani I, Lu J, Itoh M, Kulik M, Zhang J, et al. Replication timing shapes the cancer epigenome and the distribution of chromosomal rearrangements. bioRxiv [Preprint]. 2018. doi:10.1101/329813.
10. Zhao Y, et al. Collective regulation of chromatin modifications coordinates gene expression profiles. Sci Direct (Elsevier); [year not available]:[pages].
11. Rivera-Mulia JC, et al. Replication timing and epigenome remodelling are associated with the nature of pluripotency. Nat Commun. 2019;10(1):4239. doi:10.1038/s41467-019-08302-1.
12. Yoshida M, Furumai R, Nishiyama M, Komatsu Y, Nishino N, Horinouchi S. Inhibition of histone deacetylase in cancer cells: role in anti-tumor therapy. Cancer Chemother Pharmacol. 2010;66(4):739–748.
13. Egger G, Liang G, Aparicio A, Jones PA. Epigenetics in human disease and prospects for epigenetic therapy. Nature. 2005;429(6990):457–463.
14. Sengupta S, et al. Targeting the 3D genome by anthracyclines. bioRxiv [Preprint]. 2024. doi:10.1101/2024.02.06.594639.
15. Qin T, et al. Resistance to decitabine and 5-azacytidine arises from adaptive responses of the pyrimidine metabolism pathway. bioRxiv [Preprint]. 2020. doi:10.1101/2020.07.22.216531.
16. Faivre EJ, McDaniel KF, Albert DH, Mantena SR, Plotnik JP, Wilcox D, et al. Bromodomain and extraterminal (BET) proteins as therapeutic targets. Pharmacol Rev. 2023;75(3):876–917. doi:10.1124/pharmrev.122.000001.
17. Yasuda K, et al. Topoisomerase inhibitors increase episomal DNA and damage response in cancer cells. Mol Cell Oncol. 2023;10(3):e10610421.
18. Issa JP, Karpf AR. The pharmacoepigenetic paradigm in cancer treatment. Trends Cancer Res. 2024;[vol(issue)]:[pages]. PMID:11076712.
19. Sancar A, et al. Time-of-day specificity of anticancer drugs targets the cancer circadian clock. Science. 2021;372(6542):eabc5746.
20. Yoshida M, Furumai R, Nishiyama M, Komatsu Y, Nishino N, Horinouchi S. Inhibition of histone deacetylase in cancer cells. Mol Cancer Ther. 2010;9(5):1255–1265. 21. Palii SS, Van Emburgh BO, Sankpal UT, Brown KD, Robertson KD. DNMT inhibitors increase methylation within the p21CIP1/WAF1 promoter in leukemia cells. Oncotarget. 2019;10(3):349–364. PMID:6491738.
22. FDA. Table of pharmacogenetic associations. U.S. Food & Drug Administration. 2022. Available from: https://www.fda.gov/medical-devices/table-pharmacogenetic-associations.
23. Ryba T, Battaglia D, Pope BD, Hiratani I, Gilbert DM. Genome-scale analysis of replication timing and its correlation with metabolic selection. Nat Commun. 2012;3:692. doi:10.1038/ncomms1982.
24. Wu G, Bronson RT, McKeon F. Targeting chromatin-remodeling factors in cancer. Nat Rev Cancer. 2022;22(4):239–254. PMID:9655648.
25. Conti C, Seiler JA, Pommier Y. The mammalian DNA replication fork: structure and dynamics. Mol Biol Cell. 2007;18(8):3059–3069.
26. Andric V, et al. DNA damage, demethylation and anticancer implications of chromatin remodeling. Sci Rep. 2023;13(1):1634. doi:10.1038/s41598-023-32509-4.
27. Sogaard KC, et al. The anti-cancer drugs curaxins target spatial genome organization. Nat Commun. 2019;10(1):1101. doi:10.1038/s41467-019-09500-7.
28. Christodoulou D, et al. Epigenetic drugs in cancer therapy. Front Oncol. 2025;15(1):11865116. doi:10.3389/fonc.2025.11865116.
29. Oyer J, et al. Select EZH2 inhibitors enhance viral mimicry and immune response. Sci Adv. 2024;10(7):adk4423.
30. Sengupta S, et al. Targeting the 3D genome by anthracyclines. Nat Commun. 2024;15(1):39463926.
31. Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O, et al. A novel epidrug therapy based on BET inhibition. Nature. 2017;529(7587):551–554. doi:10.1038/nature16507.
32. Ju BG, Lunyak VV, Perissi V, Garcia-Bassets I, Rose DW, Glass CK, et al. Chromatin remodelling at the topoisomerase IIβ–mediated break promotes transcriptional activation. Nature. 2006;440(7088):556–560. doi:10.1038/nature04647.
33. Alexandrov LB, Ju YS, Haase K, Van Loo P, Martincorena I, Nik-Zainal S, et al. Cell-type specificity of the human mutation landscape. Nature. 2023;619(7970):117–123. PMID:10300547.
34. Daly AK. The case of pharmacogenetic studies in oncology. Pharmacogenomics J. 2011;11(1):1–6. PMID:4961927.
35. Rivera-Mulia JC, Buckley Q, Sasaki T, Zimmerman J, Didier RA, Nazor KL, et al. Replication timing and epigenome remodelling are associated with the nature of pluripotency. Nat Commun. 2019;10(1):4239. doi:10.1038/s41467-019-08302-1.
International Journal of Molecular Biotechnological Research
| Volume | 04 | |
| Issue | 01 | |
| Received | 21/03/2026 | |
| Accepted | 14/04/2026 | |
| Published | 25/04/2026 | |
| Publication Time | 35 Days |